N 3393

Drug Profile

N 3393

Latest Information Update: 11 Sep 2000

Price : $50

At a glance

  • Originator Nisshin Pharma
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuroprotection

Most Recent Events

  • 11 Sep 2000 Discontinued-Preclinical for Neuroprotection in Japan (Unknown route)
  • 20 Nov 1996 Preclinical development for Neuroprotection in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top